Circulating microRNA-200 family as diagnostic marker in hepatocellular carcinoma

PLoS ONE

Volumn 10, Issue 10, 2015, Pages

  Dhayat, Sameer A ^a   Hüsing, Anna ^a   Senninger, Norbert ^a   Schmidt, Hartmut H ^a   Haier, Jörg ^a   Wolters, Heiner ^a   Kabar, Iyad ^a  

^a UNIVERSITY HOSPITAL MÜNSTER   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

MICRORNA 141; MICRORNA 200; MICRORNA 200A; MICRORNA; MIRN141 MICRORNA, HUMAN; MIRN200 MICRORNA, HUMAN; TUMOR MARKER;

AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER PROGNOSIS; CARCINOGENESIS; CHILD PUGH SCORE; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC VALUE; DOWN REGULATION; FACTORIAL ANALYSIS; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; POLYMERASE CHAIN REACTION; PROSPECTIVE STUDY; RECEIVER OPERATING CHARACTERISTIC; ADULT; AGED; BLOOD; CARCINOMA, HEPATOCELLULAR; CASE CONTROL STUDY; DIFFERENTIAL DIAGNOSIS; FEMALE; LIVER NEOPLASMS; MALE; MIDDLE AGED; YOUNG ADULT;

ADULT; AGED; BIOMARKERS, TUMOR; CARCINOMA, HEPATOCELLULAR; CASE-CONTROL STUDIES; DIAGNOSIS, DIFFERENTIAL; FEMALE; HUMANS; LIVER CIRRHOSIS; LIVER NEOPLASMS; MALE; MICRORNAS; MIDDLE AGED; ROC CURVE; YOUNG ADULT;

EID: 84948670132     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0140066     Document Type: Article

References (26)

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015; 65(1):5-29. Epub 2015/01/07. doi: 10.3322/caac.21254 PMID: 25559415.
2. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010; 127(12):2893-917. Epub 2011/02/26. doi: 10.1002/ijc. 25516 PMID: 21351269.
3. Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology. 2011; 53 (3):1020-2. Epub 2011/03/05. doi: 10.1002/hep.24199 PMID: 21374666; PubMed Central PMCID: PMC3084991.
4. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. Eur J Cancer. 2012; 48(5):599-641. Epub 2012/03/20. doi: 10.1016/j.ejca.2011.12.021 PMID: 22424278.
5. Abu El Makarem M. An overview of biomarkers for the diagnosis of hepatocellular carcinoma. Hepat Mon. 2012; 12(10 HCC):e6122. Epub 2012/11/20. PMID: 23162601; PubMed Central PMCID: PMC3496856.
6. Huang YS, Dai Y, Yu XF, Bao SY, Yin YB, Tang M, et al. Microarray analysis of microRNA expression in hepatocellular carcinoma and non-tumorous tissues without viral hepatitis. J Gastroenterol Hepatol. 2008; 23(1):87-94. Epub 2008/01/04. doi: 10.1111/j.1440-1746.2007.05223.x PMID: 18171346.
7. Ji J, Wang XW. New kids on the block: diagnostic and prognostic microRNAs in hepatocellular carcinoma. Cancer Biol Ther. 2009; 8(18):1686-93. Epub 2009/11/11. PMID: 19901517.
8. Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL, et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A. 2008; 105 (30):10513-8. Epub 2008/07/30. doi: 10.1073/pnas.0804549105 PMID: 18663219; PubMed Central PMCID: PMC2492472.
9. Chen X, Hu Z, Wang W, Ba Y, Ma L, Zhang C, et al. Identification of ten serum microRNAs from a genome-wide serum microRNA expression profile as novel noninvasive biomarkers for nonsmall cell lung cancer diagnosis. Int J Cancer. 2012; 130(7):1620-8. Epub 2011/05/11. doi: 10.1002/ijc.26177 PMID: 21557218.
10. Dhayat SA, Mardin WA, Kohler G, Bahde R, Vowinkel T, Wolters H, et al. The microRNA-200 family-a potential diagnostic marker in hepatocellular carcinoma? J Surg Oncol. 2014; 110(4):430-8. Epub 2014/06/05. doi: 10.1002/jso.23668 PMID: 24895326.
11. Bojmar L, Karlsson E, Ellegard S, Olsson H, Bjornsson B, Hallbook O, et al. The role of microRNA-200 in progression of human colorectal and breast cancer. PLoS One. 2013; 8(12):e84815. Epub 2014/01/ 01. doi: 10.1371/journal.pone.0084815 PMID: 24376848; PubMed Central PMCID: PMC3869924.
12. Romero-Perez L, Lopez-Garcia MA, Diaz-Martin J, Biscuola M, Castilla MA, Tafe LJ, et al. ZEB1 overexpression associated with E-cadherin and microRNA-200 downregulation is characteristic of undifferentiated endometrial carcinoma. Mod Pathol. 2013; 26(11):1514-24. Epub 2013/06/08. doi: 10.1038/ modpathol.2013.93 PMID: 23743934.
13. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001; 25(4):402-8. Epub 2002/02/16. doi: 10.1006/ meth.2001.1262 PMID: 11846609.
14. Khare S, Zhang Q, Ibdah JA. Epigenetics of hepatocellular carcinoma: role of microRNA. World J Gastroenterol. 2013; 19(33):5439-45. Epub 2013/09/12. doi: 10.3748/wjg.v19.i33.5439 PMID: 24023486; PubMed Central PMCID: PMC3761096.
15. Zhou J, Yu L, Gao X, Hu J, Wang J, Dai Z, et al. Plasma microRNA panel to diagnose hepatitis B virusrelated hepatocellular carcinoma. J Clin Oncol. 2011; 29(36):4781-8. Epub 2011/11/23. doi: 10.1200/ JCO.2011.38.2697 PMID: 22105822.
16. Xu J, Wu C, Che X, Wang L, Yu D, Zhang T, et al. Circulating microRNAs, miR-21, miR-122, and miR- 223, in patients with hepatocellular carcinoma or chronic hepatitis. Mol Carcinog. 2011; 50(2):136-42. Epub 2011/01/14. doi: 10.1002/mc.20712 PMID: 21229610.
17. Huang Z, Huang D, Ni S, Peng Z, Sheng W, Du X. Plasma microRNAs are promising novel biomarkers for early detection of colorectal cancer. Int J Cancer. 2010; 127(1):118-26. Epub 2009/10/31. doi: 10. 1002/ijc.25007 PMID: 19876917.
18. Zhu C, Ren C, Han J, Ding Y, Du J, Dai N, et al. A five-microRNA panel in plasma was identified as potential biomarker for early detection of gastric cancer. Br J Cancer. 2014; 110(9):2291-9. Epub 2014/ 03/07. doi: 10.1038/bjc.2014.119 PMID: 24595006; PubMed Central PMCID: PMC4007222.
19. Li A, Yu J, Kim H, Wolfgang CL, Canto MI, Hruban RH, et al. MicroRNA array analysis finds elevated serum miR-1290 accurately distinguishes patients with low-stage pancreatic cancer from healthy and disease controls. Clin Cancer Res. 2013; 19(13):3600-10. Epub 2013/05/24. doi: 10.1158/1078-0432. CCR-12-3092 PMID: 23697990; PubMed Central PMCID: PMC3707520.
20. Takeshita N, Hoshino I, Mori M, Akutsu Y, Hanari N, Yoneyama Y, et al. Serum microRNA expression profile: miR-1246 as a novel diagnostic and prognostic biomarker for oesophageal squamous cell carcinoma. Br J Cancer. 2013; 108(3):644-52. Epub 2013/01/31. doi: 10.1038/bjc.2013.8 PMID: 23361059; PubMed Central PMCID: PMC3593570.
21. Tan Y, Ge G, Pan T, Wen D, Chen L, Yu X, et al. A serum microRNA panel as potential biomarkers for hepatocellular carcinoma related with hepatitis B virus. PLoS One. 2014; 9(9):e107986. Epub 2014/09/ 23. doi: 10.1371/journal.pone.0107986 PMID: 25238238; PubMed Central PMCID: PMC4169601.
22. Li G, Shen Q, Li C, Li D, Chen J, He M. Identification of circulating MicroRNAs as novel potential biomarkers for hepatocellular carcinoma detection: a systematic review and meta-analysis. Clin Transl Oncol. 2015. Epub 2015/05/10. doi: 10.1007/s12094-015-1294-y PMID: 25956842.
23. Rekker K, Saare M, Roost AM, Kaart T, Soritsa D, Karro H, et al. Circulating miR-200-family micro- RNAs have altered plasma levels in patients with endometriosis and vary with blood collection time. Fertil Steril. 2015. Epub 2015/07/25. doi: 10.1016/j.fertnstert.2015.06.029 PMID: 26206343.
24. Liu Y, Ding Y, Huang J, Wang S, Ni W, Guan J, et al. MiR-141 suppresses the migration and invasion of HCC cells by targeting Tiam1. PLoS One. 2014; 9(2):e88393. Epub 2014/02/20. doi: 10.1371/journal. pone.0088393 PMID: 24551096; PubMed Central PMCID: PMC3923786.
25. Wang Y, Gao Y, Shi W, Zhai D, Rao Q, Jia X, et al. Profiles of differential expression of circulating microRNAs in hepatitis B virus-positive small hepatocellular carcinoma. Cancer Biomark. 2015; 15 (2):177-86. Epub 2014/12/19. doi: 10.3233/CBM-140451 PMID: 25519019.
26. Uhlmann S, Zhang JD, Schwager A, Mannsperger H, Riazalhosseini Y, Burmester S, et al. miR-200bc/ 429 cluster targets PLCgamma1 and differentially regulates proliferation and EGF-driven invasion than miR-200a/141 in breast cancer. Oncogene. 2010; 29(30):4297-306. Epub 2010/06/02. doi: 10.1038/ onc.2010.201 PMID: 20514023.